Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea

Many chronic obstructive pulmonary disease (COPD) patients receiving monotherapy continue to experience symptoms, exacerbations and poor quality of life. This study aimed to assess the efficacy and safety of direct switch from once-daily tiotropium (TIO) 18 μg to indacaterol/glycopyrronium (IND/GLY)...

Full description

Saved in:
Bibliographic Details
Published in:Tuberculosis and respiratory diseases 2021, 84(2), 386, pp.96-104
Main Authors: Lee, Sang Haak, Rhee, Chin Kook, Yoo, Kwangha, Park, Jeong Woong, Yong, Suk Joong, Kim, Jusang, Lee, Taehoon, Lim, Seong Yong, Lee, Ji-Hyun, Park, Hye Yun, Moon, Minyoung, Jung, Ki-Suck
Format: Article
Language:English
Subjects:
indacaterol/glycopyrronium
korea
long-acting muscarinic antagonist
long-acting β-agonist
lung function
Original
tiotropium
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many chronic obstructive pulmonary disease (COPD) patients receiving monotherapy continue to experience symptoms, exacerbations and poor quality of life. This study aimed to assess the efficacy and safety of direct switch from once-daily tiotropium (TIO) 18 μg to indacaterol/glycopyrronium (IND/GLY) 110/50 μg once-daily in COPD patients in Korea. This was a randomized, open-label, parallel group, 12-week trial in mild-to-moderate COPD patients who received TIO 18 μg once-daily for ≥12 weeks prior to study initiation. Patients aged ≥40 years, with predicted postbronchodilator forced expiratory volume in 1 second (FEV1) ≥50%, post-bronchodilator FEV1/forced vital capacity
ISSN:1738-3536
2005-6184
DOI:10.4046/trd.2020.0109